| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 335.6 | 337.9 |
| Gross profit | 189.1 | 166.1 |
| Profit before tax | 26.0 | 4.3 |
| Net income | 19.8 | 2.9 |
| EPS (diluted, $ a share) | $0.66 | $0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +592.4% |
|---|---|
| Revenue, year on year | -0.7% |
| Gross margin | 56.4% |
| Operating margin | 11.1% |
10-Q filed with the SEC, NYSE: CNMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Conmed Corp: key numbers
- Share price
- $49.35Close, Nov 16
- Market cap
- $1.47B
- Shares outstanding
- 29.8MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Conmed Corp
All →Conmed Financial Results
CONMED Corporation reported third quarter 2026 financial results with sales of $335.6 million, a slight decrease of 0.7% year-over-year, though organic constant currency sales grew 6.7% when excluding strategic product exits. The company updated its full-year 2026 guidance, now expecting net sales between $1.360 billion and $1.366 billion and adjusted diluted EPS of $4.54 to $4.61.
- Term
- Q3 2026
“Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team’s strong execution.”
Patrick J. Beyer, CONMED’s President and Chief Executive Officer
“Looking ahead, our global team remains focused on executing our growth strategy to expand awareness and adoption of our key product platforms across the minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair markets.”
Patrick J. Beyer, CONMED’s President and Chief Executive Officer